The implementation of decentralised clinical trials amid the pandemic involves significant changes to conventional procedures.

GlobalData conducted a survey to identify the top changes that the companies feel will be necessary while transitioning to DCTs.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Systems integration and alignment to drive decentralised clinical trialsBiggest Changes Needed to Pivot to Decentralised Clinical Trials

According to the survey results, around 17% of the respondents feel that systems integrations and alignment will be required while switching to DCTs.

It is followed closely by process changes and alignment (16%) and training (16%).

Around 15% of the respondents opined that changes to regulatory/ operational risk assessments will be the biggest change needed to pivot decentralised trials, while another 13% highlighted adjustments in upfront planning and coordination for study execution.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The percentage of respondents who said that changes in study design will be required to transition to DCT stands at 13%.

On the other hand, only 9% stated that changes in the organisational structure will be required indicating that the organisations feel that the distribution of work will be easier while switching to decentralised trials.

The analysis is based on responses received for the Coronavirus Survey – COVID-19 and Decentralised Clinical Trials conducted by GlobalData between 04 June and 22 June 2020.